Market Place
Sourcing Support
Chiesi, Protalix Announce EMA Validation for Pegunigalsidase Alfa
09 Dec 2024 //
PR NEWSWIRE
Protalix BioTherapeutics Reports Q3 2024 Results & Updates
14 Nov 2024 //
PR NEWSWIRE
Protalix to Announce Q3 2024 Results on Nov 14, 2024
07 Nov 2024 //
PR NEWSWIRE
Protalix BioTherapeutics to Present at H.C. Wainwright Annual Conference
04 Sep 2024 //
PR NEWSWIRE
Protalix BioTherapeutics Repays Senior Secured Convertible Promissory Notes
03 Sep 2024 //
PR NEWSWIRE
Protalix BioTherapeutics Reports Q2 2024 Financial And Business Results
14 Aug 2024 //
PR NEWSWIRE
Protalix Reports Q2 2024 Financial And Business Results
14 Aug 2024 //
PR NEWSWIRE
Protalix BioTherapeutics To Announce Q2 2024 Results On Aug 14
07 Aug 2024 //
PR NEWSWIRE
Prolatix To Host Investor Day On Fabry, Gout Treatment Landscapes
13 Jun 2024 //
PR NEWSWIRE
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
30 May 2024 //
PR NEWSWIRE
Protalix BioTherapeutics Q1 2024 Financials, Business
10 May 2024 //
PR NEWSWIRE
Protalix To Announce Q1 2024 Results On May 10
03 May 2024 //
PR NEWSWIRE
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial Results
07 Mar 2024 //
PR NEWSWIRE
Protalix Bio to Participate in the 2024 BIO CEO & Investor Conference
23 Feb 2024 //
PR NEWSWIRE
Protalix BioTherapeutics Issues 2024 Letter to Stockholders
26 Dec 2023 //
PR NEWSWIRE
Protalix BioTherapeutics Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
PR NEWSWIRE
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial Results
30 Oct 2023 //
PR NEWSWIRE
Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
09 Oct 2023 //
PR NEWSWIRE
Protalix Appoints Eliot Richard Forster as Chairman of its Board of Directors
12 Sep 2023 //
PR NEWSWIRE
Protalix to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
PR NEWSWIRE
Protalix BioTherapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
PR NEWSWIRE
Protalix to Present at the Canaccord Genuity 43rd Annual Growth Conference
01 Aug 2023 //
PR NEWSWIRE
Protalix BioTherapeutics to Announce Second Quarter 2023 Financial Results
31 Jul 2023 //
PR NEWSWIRE
Protalix to Host In-Person KOL Breakfast following the Approval of Elfabrio
08 Jun 2023 //
PR NEWSWIRE
Protalix BioTherapeutics set to join Russell 3000® Index
23 May 2023 //
PR NEWSWIRE
Chiesi, Protalix`s Fabry disease approved as Elfabrio joins Fabrazyme
10 May 2023 //
ENDPTS
Europe signs off on Protalix, Chiesi`s Fabry disease treatment
06 May 2023 //
FIERCE PHARMA
Protalix BioTherapeutics Reports 1Q 2023 Financial and Business Results
04 May 2023 //
PR NEWSWIRE
Protalix BioTherapeutics to Announce 1Q FYR & Business Results on May 4, 2023
27 Apr 2023 //
PR NEWSWIRE
Protalix Announces First Patient Dosed in First in Human PI Trial of PRX-115
21 Mar 2023 //
PR NEWSWIRE
Protalix Issues Statement Related to Silicon Valley Bank and Signature Bank
13 Mar 2023 //
PR NEWSWIRE
Protalix & Chiesi gain positive opinion for pegunigalsidase alfa
06 Mar 2023 //
PHARMATIMES
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results
27 Feb 2023 //
PR NEWSWIRE
Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa
25 Feb 2023 //
BIOSPACE
Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023
21 Feb 2023 //
PR NEWSWIRE
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv
21 Dec 2022 //
PRNEWSWIRE
Protalix & Chiesi Announce FDA Acceptance of BLA for Pegunigalsidase Alfa
05 Dec 2022 //
PRNEWSWIRE
Protalix Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102
04 Dec 2022 //
PRNEWSWIRE
After CRL, drug developer duo resubmits its experimental drug to the FDA
15 Nov 2022 //
ENDPTS
Protalix & Chiesi Announce Resubmission of BLA to FDA for Pegunigalsidase Alfa
14 Nov 2022 //
PRNEWSWIRE
Protalix BioTherapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
PRNEWSWIRE
Protalix to Present in Person at the Global Investment Conference
12 Sep 2022 //
PRNEWSWIRE
Protalix Bio to Present at the H.C. Wainwright Global Investment Conference
06 Sep 2022 //
PRNEWSWIRE
Protalix BioTherapeutics Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
PRNEWSWIRE
Protalix Bio to Announce Second Quarter 2022 Financial and Business Results
08 Aug 2022 //
PRNEWSWIRE
Protalix Bio Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors
30 Jun 2022 //
PRNEWSWIRE
Protalix BioTherapeutics Reports First Quarter 2022 Financial
16 May 2022 //
PRNEWSWIRE
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
31 Mar 2022 //
PRNEWSWIRE
Chiesi and Protalix announce Phase III data from BRIGHT study in Fabry disease
19 Mar 2022 //
THEPHARMALETTER
Protalix Bio, Chiesi Global Rare Diseases Submit MAA to EMA for PRX-102
24 Feb 2022 //
PRNEWSWIRE
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022
03 Feb 2022 //
PRNEWSWIRE
Protalix Bio Reports Q3 2021 Financial Results, Provides Business Update
15 Nov 2021 //
PRNEWSWIRE
Protalix Biotherapeutics & Chiesi Global Rare Diseases Provide Regulatory Update
11 Oct 2021 //
PRNEWSWIRE
Protalix sees a path for Fabry resubmission down the line
11 Oct 2021 //
FIERCEBIOTECH
Protalix BioTherapeutics Announces Private Note Exchange
13 Aug 2021 //
PR NEWSWIRE
Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021
28 Jun 2021 //
PR NEWSWIRE
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results
13 May 2021 //
PRNEWSWIRE
Protalix and Chiesi Global Rare Diseases Receive Complete Response Letter
28 Apr 2021 //
PRNEWSWIRE
Protalix and Chiesi Global Rare Diseases Announce Positive Topline Results
23 Feb 2021 //
BIOSPACE
Protalix and Chiesi Global Rare Diseases Announce Positive Topline Results
23 Feb 2021 //
PRNEWSWIRE
